文献速递妇科

替西罗莫司联合卡铂和紫杉醇后续替西罗莫司巩固治疗透明细胞卵巢癌的II期评估:一项NRG肿瘤学试验

A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
PubMed 文献 · Gynecol Oncol · 2022-10-14

本研究为II期试验,纳入90例新诊断III或IV期透明细胞卵巢癌患者,接受卡铂/紫杉醇联合替西罗莫司治疗,后续替西罗莫司巩固治疗。主要终点12个月无进展生存(PFS)与历史对照相比无统计学显著提高。在最佳减瘤患者中,54%的患者PFS超过12个月。

要点

  • 卡铂/紫杉醇联合替西罗莫司方案耐受性良好。
  • 最佳减瘤患者中54%达到PFS超过12个月。
  • 12个月PFS与历史对照相比无统计学显著差异。

核心结论

  • 卡铂/紫杉醇联合替西罗莫司方案耐受性良好。
  • 在最佳减瘤患者中,54%的患者PFS超过12个月。
  • 该方案与历史对照相比未在12个月时统计学显著提高PFS。
  • 美国/韩国与日本之间、亚洲人与非亚洲人之间的PFS或OS无统计学显著差异。

研究设计与样本

  • II期临床试验(NRG肿瘤学试验),纳入90例新诊断III或IV期透明细胞卵巢癌患者,其中美国/韩国45例,日本45例。

主要发现

  • 22%的患者接受≤6周期治疗,28%完成全部17周期化疗。
  • 美国/韩国中位PFS为11个月,中位OS为23个月;日本中位PFS为12个月,中位OS为26个月。
  • 美国亚最佳减瘤患者中无PFS超过12个月,最佳减瘤患者中49%有PFS超过12个月;日本相应比例为25%和59%。
  • 最常见3-4级不良事件为中性粒细胞减少、白细胞减少、贫血、血小板减少、高血压、高甘油三酯血症和口腔黏膜炎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The primary objective of the study was to estimate the 12-month progression-free survival (PFS) for carboplatin/paclitaxel + temsirolimus in women with newly diagnosed clear cell ovarian cancer (CCOC), compared to historical controls in this patient population. METHODS: Patients with Stage III or IV CCOC were treated with Paclitaxel 175 mg/m2 on Day 1, Carboplatin AUC 6 Day 1, and temsirolimus (CCI-779) 25 mg IV Days 1 and 8 every 3 weeks for Cycles 1-6 or disease progression, followed by consolidation therapy with temsirolimus 25 mg Days 1, 8, and 15 every 3 weeks cycles 7-17 or until disease progression. RESULTS: Ninety patients were accrued to the study: 45 in the US and Korea (US/Korea) and 45 in Japan. Twenty-two percent received ≤6 cycles of therapy while 28% completed all 17 cycles of chemotherapy. Median PFS (OS) was 11 (23) months for US/Korea and 12 (26) months for Japan. In the US, none of suboptimally debulked patients had PFS >12 months, and 49% of optimal patients did, compared to 25% and 59% in Japan. Most common grade 3-4 adverse events were neutropenia, leukopenia, anemia, thrombocytopenia, hypertension, hypertriglyceridemia, and oral mucositis. CONCLUSION: The carboplatin/paclitaxel + temsirolimus regimen was well tolerated. In optimally debulked patients, 54% had a PFS >12 months. This regimen did not statistically significantly increase PFS at 12 months compared to historical controls. No statistically significant differences in PFS or OS were observed between US/Korea vs Japan, or Asians vs non-Asians.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Farley JH, Brady WE, O'Malley D, et al. A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial. Gynecol Oncol. 2022. PMID: 36244829. doi:10.1016/j.ygyno.2022.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。